Decreased Serum miR-1296 may Serve as an Early Biomarker for the Diagnosis of Non-Alcoholic Fatty Liver Disease.
Circulating microRNA has become a candidate biomarker for many diseases. The purpose of this study was to investigate the significance of miR-1296 as a non-invasive biomarker in nonalcoholic fatty liver disease (NAFLD). Serum samples were collected from normal people and NAFLD patients for biochemical detection. Serum microRNAs were isolated by the NucleoZOL method, and the stem-loop method was used to reverse transcribe the DNA. The relative quantification of miR-1296 was performed by SYBR Green method. Spearman's method was used to analyze the correlation between miR-1296 and serum biochemical parameters. By using 2-∆∆CT method, we found that, compared with the normal control group, the expression of serum miR-1296 increased in patients with normal lipid NAFLD and those with hyperlipidemia NAFLD. At the same time, the expression of microRNA-1296 in the NAFLD hyperlipidemia group increased more significantly than that in the NFALD group with normal lipid. Spearman's correlation assay demonstrated that the correlation between the expression of miR-1296 and blood lipids, including TC, TG, HDL-c, and LDL-c, was TC (r = 0.4951, p = 0.0013), TG (r = 0.054, p = 0.6425), HDL-C (r = 0.3435, p = 0.07522), and LDL-C (r = 0.3307, p = 0.0699. The data showed that miR-1296 was positively correlated with serum TC level. In summary, serum microRNA-1296 is a more sensitive marker of NAFLD than blood lipids, which provides a new method for noninvasive early screening of NAFLD.